Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lytix Biopharma AS ( (DE:6BG) ) has shared an update.
Lytix Biopharma AS announced that its partner, Verrica Pharmaceuticals, will present new data from a Phase II trial of VP-315 for treating basal cell carcinoma at the Society for Immunotherapy of Cancer Annual Meeting. This presentation highlights the potential of Lytix’s technology platform and its progress in advancing oncolytic peptide approaches, marking a significant step in the company’s industry positioning and offering promising implications for stakeholders.
More about Lytix Biopharma AS
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company specializing in immuno-oncology. It focuses on developing novel host-defense peptide-derived molecules to boost anti-cancer immunity, with its lead product being Ruxotemitide (formerly LTX-315), a first-in-class oncolytic molecule. The company is listed on Euronext Growth Oslo under the ticker LYTIX.
Average Trading Volume: 46,245
Current Market Cap: NOK491.5M
For detailed information about 6BG stock, go to TipRanks’ Stock Analysis page.